Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Provectus Signs LOI for Cancer Drug with Boehringer Ingelheim China

publication date: Jul 2, 2015
Provectus Biopharma, a clinical stage oncology pharma headquartered in Tennessee, has signed an LOI with Boehringer Ingelheim (China) Investment Co. The LOI proposes that Boehringer will support Provectus' efforts to register PV-10, the company's lead cancer molecule, in China. In return, Boehringer will have first priority to collaborate in Provectus' China commercialization of PV-10. One year ago, Provectus signed an LOI with Sinopharm for China rights to PV-10. The agreement, which has been extended several times, will expire in two weeks. More details....

Stock Symbol: (NYSE: PVCT)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital